A study funded by St. Jude Medical shows that its PressureWire fractional flow reserve technology is cheaper over the long run that optimal medical therapy, sending STJ shares up slightly today.
Results from the Fame II study comparing St. Jude Medical 's (NYSE:STJ ) PressureWire fractional flow reserve device with optimal medical care show that FFR-guided coronary interventions are more cost-effective, sending STJ shares up nearly 2% today on Wall Street.
The St. Paul, Minn.-based medical device company funded the trial, which earlier this year demonstrated that the FFR-guided PCI arm patients fared better than the control arm. Now the company said the data also show that the procedure is less expensive than medical therapy alone over the long term.
Dr. William Fearon of Stanford University, presenting data at the Transcatheter Cardiovascular Therapeutics conference today in Miami, said that the previous Courage trial influences cardiologists to let optimal medical therapy run its course before attempting PCI, according to heartwire .